Early trial aims to stop Slow-Growing blood cancer in its tracks
NCT ID NCT02603887
Summary
This small, early-stage study is testing whether the immunotherapy drug pembrolizumab can help control smoldering multiple myeloma, a slow-growing blood cancer that has a high risk of turning into active disease. The drug works by helping the body's own immune system recognize and attack the cancer cells. Researchers are giving the drug to about 20 high-risk patients to see if it can delay or prevent the cancer from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.